Hyaluronidase
(Synonyms: 透明质酸酶) 目录号 : GC19790
透明质酸酶(Hyaluronidase)是一种天然酶,可降解透明质酸,具有高度的特异性和水解活性。
Cas No.:37326-33-3;9001-54-1
Sample solution is provided at 25 µL, 10mM.
Hyaluronidase is a natural enzyme that can degrade hyaluronic acid and has high specificity and hydrolytic activity[1]. The mechanism of action of hyaluronidase is mainly to reduce the viscosity and molecular weight of hyaluronic acid by cutting the β-1,4-glucosidic bond of hyaluronic acid[2]. In humans, six different hyaluronidases have been identified, HYAL 1-4, HYAL-P1 and PH-20, of which PH-20 has the strongest biological activity[3]. Hyaluronidase is often used to improve the tissue permeability of drugs, promote drug absorption, and can also reverse adverse reactions caused by hyaluronic acid fillers[4].
In vitro, hyaluronidase (100mU/ml) treatment of astrocytes that knocked down CD44 expression for 24 hours enhanced the activity of Rac1, causing the cells to become "star-like" morphology[5]. Hyaluronidase (12U/mL) treats MM6 cells, directly targeting HA and eliminating the HA signal[6].
In vivo, hyaluronidase treatment of lymphedema model mice rapidly reduced the size of the edema area and enhanced lymphangiogenesis in the edematous limbs [7].
References:
[1] Menzel E J, Farr C. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses[J]. Cancer letters, 1998, 131(1): 3-11.
[2] Tao L, Song F, Xu N, et al. New insights into the action of bacterial chondroitinase AC I and hyaluronidase on hyaluronic acid[J]. Carbohydrate polymers, 2017, 158: 85-92.
[3] Weber G C, Buhren B A, Schrumpf H, et al. Clinical applications of hyaluronidase[J]. Therapeutic Enzymes: Function and Clinical Implications, 2019: 255-277.
[4] Vartanian A J, Frankel A S, Rubin M G. Injected hyaluronidase reduces restylane-mediated cutaneous augmentation[J]. Archives of Facial Plastic Surgery, 2005.
[5] Konopka A, Zeug A, Skupien A, et al. Cleavage of hyaluronan and CD44 adhesion molecule regulate astrocyte morphology via Rac1 signalling[J]. PloS one, 2016, 11(5): e0155053.
[6] Zahreddine H A, Culjkovic-Kraljacic B, Emond A, et al. The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity[J]. Elife, 2017, 6: e29830.
[7] Roh K, Cho S, Park J, et al. Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model[J]. Experimental Biology and Medicine, 2017, 242(6): 584-592.
透明质酸酶(Hyaluronidase)是一种天然酶,可降解透明质酸,具有高度的特异性和水解活性[1]。透明质酸酶的作用机制主要是通过切断透明质酸的β-1,4-糖苷键,降低透明质酸的黏度和分子量[2]。在人体中,已经鉴定了六种不同的透明质酸酶,HYAL 1-4、HYAL-P1和PH-20,其中PH-20具有最强的生物活性[3]。透明质酸酶常用于改善药物的组织渗透性,促进药物吸收,还可逆转透明质酸填充剂引起的不良反应[4]。
在体外,透明质酸酶(100mU/ml)处理敲低了CD44表达的星形胶质细胞24h,会增强Rac1的活性,导致细胞变成“星状”形态[5]。透明质酸酶(12U/mL)处理MM6细胞,直接靶向HA,消除了HA信号[6]。
在体内,透明质酸酶治疗淋巴水肿模型小鼠,水肿区域体积迅速变小,增强了水肿肢体的淋巴管生成[7]。
Cell experiment [1]: | |
Cell lines | astrocytes |
Preparation method | Astrocytes cultured in vitro were starved overnight in medium without serum and then incubated for 24h with hyaluronidase type IV-S (100mU/ml), heat-inactivated hyaluronidase or deionized sterile water. |
Reaction Conditions | 100mU/ml; 24h |
Applications | hyaluronidase treatment, as well as knockdown of CD44, in astrocytes result in a “stellate”-like morphology. |
References: [1] Konopka A, Zeug A, Skupien A, et al. Cleavage of hyaluronan and CD44 adhesion molecule regulate astrocyte morphology via Rac1 signalling[J]. PloS one, 2016, 11(5): e0155053. |
Cas No. | 37326-33-3;9001-54-1 | SDF | |
别名 | 透明质酸酶 | ||
分子式 | 分子量 | ||
溶解度 | 储存条件 | Store at -20°C,protect from light | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Biological Activity: ≥300U/mg
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet